Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
65.00    -0.50 (-0.76%)
Bid:
64.00
Ask:
66.00
Spread: 2.00 (3.125%)
Market Cap: £79.19m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

New distribution agreements

23 Sep 2014 07:00

RNS Number : 3099S
Venture Life Group PLC
23 September 2014
 

 

Venture Life Group plc

("Venture Life" or "the Group")

Long-term distribution agreements signed with four new partners

 

Bracknell, UK - 23 September 2014: Venture Life Group plc (AIM: VLG), the international consumer self-care group addressing the needs of the ageing population, announces that it has signed long-term product distribution agreements with four new partners. The agreements give these distributors exclusive rights to sell certain Venture Life products across a total of nine European territories, including Germany. Based on the contractual minimum purchase obligations of the partners, these four agreements combined should deliver minimum annual revenues of €0.24 million in year 1, rising to €0.59 million in year 5, and totalling €5.1 million over the ten year term of the agreements.

 

The agreements are with the following companies:

 

Distributor

Venture Life product

Territories

Expected first revenues for VLG

Valeant

Procto-eze cream

Six, including Germany

H1 2015

Lyfis

Procto-eze cream and cleanser

Iceland

H1 2015

Symphar

Procto-eze cream

Poland

H1 2015

Deltapharma

Original Bioscalin shampoo and capsules

Albania

H1 2015

 

In addition to these agreements, the Group has already signed a further seven product partnering deals during 2014, as well as four extension deals signed with existing partners for additional Venture Life products. The Group now has distribution agreements covering all 14 of its current branded products in a combined 42 territories worldwide, and its unbranded products manufactured by Biokosmes are sold in over 10 countries.

Jerry Randall, Chief Executive Officer of Venture Life, commented:

"We are delighted to broaden further our partner base in Europe, and to see further validation of our model and products through a long term agreement with Valeant, a global top 50 pharmaceutical company. We are delivering increasing benefits from the merger with Biokosmes and are seeing gathering momentum in our branded portfolio as we broaden the distribution base of our branded products. We are particularly pleased with our first distribution deal in Germany, the fourth largest economy in the world and a major European territory".

 

- Ends -

 

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer

James Hunter, Chief Financial Officer +44 (0)1344 742 870

 

 

Square1 Consulting

David Bick

Mark Longson +44 (0)20 7929 5599

 

 

JW Communications

Julia Wilson +44 (0)7818 430877

 

 

Notes to editors

 

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercializing products for the ageing population. The Group's product range and pipeline currently include food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

 

Through its topical development and manufacturing business, Biokosmes, the Group also provides development and manufacturing services to companies in the medical device and cosmetic sectors.

The Group's own branded products are currently sold or partnered in over 50 countries and currently include:

· food supplements to maintain brain function and memory;

· dermo-cosmetics for addressing the signs of skin ageing and hair loss, and

· medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.

 

The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.

 

About Procto-eze

Procto-eze helps relieve the discomfort caused by haemorrhoids.

 

About Original Bioscalin

Original Bioscalin helps control hair loss, promotes new hair growth and enhances the overall condition of hair.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADLLFLZKFFBBX
Date   Source Headline
9th Dec 20202:28 pmRNSDirector/PDMR Shareholding
8th Dec 202012:00 pmRNSResult of General Meeting and Open Offer
24th Nov 20207:00 amRNSPDMR Dealings and Issue of Equity
23rd Nov 20208:52 amRNSHolding(s) in Company
20th Nov 20201:00 pmRNSPlacing, Open Offer and Notice of General Meeting
16th Nov 20209:05 amRNSSecond Price Monitoring Extn
16th Nov 20209:00 amRNSPrice Monitoring Extension
16th Nov 20207:00 amRNSResults of in-vitro clinical trial published
9th Nov 20204:40 pmRNSSecond Price Monitoring Extn
9th Nov 20204:36 pmRNSPrice Monitoring Extension
3rd Nov 20209:33 amRNS1000 Companies to Inspire Britain 2020 Report
19th Oct 202012:24 pmRNSHolding(s) in Company
15th Oct 20202:57 pmRNSExercise of Share Options & Voting Rights
9th Oct 20201:39 pmRNSHolding(s) in Company
5th Oct 20201:21 pmRNSHolding(s) in Company
24th Sep 20207:00 amRNSHalf-year Report
25th Aug 202011:59 amRNSHolding(s) in Company
24th Aug 20207:00 amRNSKey oral care brand - clinical trial on COVID-19
20th Jul 20209:05 amRNSSecond Price Monitoring Extn
20th Jul 20209:00 amRNSPrice Monitoring Extension
20th Jul 20207:00 amRNSHalf Year Trading Update
13th Jul 20207:00 amRNSAppointment of Joint Broker
22nd Jun 20204:41 pmRNSSecond Price Monitoring Extn
22nd Jun 20204:36 pmRNSPrice Monitoring Extension
22nd Jun 202011:05 amRNSSecond Price Monitoring Extn
22nd Jun 202011:00 amRNSPrice Monitoring Extension
11th Jun 20207:00 amRNSHolding(s) in Company
9th Jun 20207:00 amRNSTrading update
3rd Jun 202010:52 amRNSResult of AGM
3rd Jun 20207:00 amRNSAGM Statement
29th May 20203:56 pmRNSHolding(s) in Company
20th May 20207:59 amRNSHolding(s) in Company
19th May 20203:26 pmRNSHolding(s) in Company
19th May 20203:25 pmRNSHolding(s) in Company
19th May 20201:29 pmRNSDirector/PDMR Shareholding
15th May 20207:00 amRNSComment on mouthwash & COVID-19 transmission
29th Apr 20204:15 pmRNSHolding(s) in Company
27th Apr 20209:06 amRNSSecond Price Monitoring Extn
27th Apr 20209:00 amRNSPrice Monitoring Extension
27th Apr 20207:00 amRNSExclusive Long Term Agreement Secured in China
16th Apr 20203:13 pmRNSHolding(s) in Company
9th Apr 20207:00 amRNSFinal Results
1st Apr 20203:10 pmRNSNotice of Results
25th Mar 20207:00 amRNSNotice of Results Update and Trading Update
9th Mar 20207:00 amRNSTrading Update and Notice of Results
21st Feb 20207:00 amRNSDirector/PDMR Shareholding
24th Jan 202012:37 pmRNSCompletion of Acquisition
9th Jan 20204:28 pmRNSDirector/PDMR Shareholding
6th Jan 20203:38 pmRNSGrant of Options
19th Dec 20197:00 amRNSAcquisition and Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.